Overview Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease Status: Recruiting Trial end date: 2022-05-01 Target enrollment: Participant gender: Summary A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease Phase: Phase 1 Details Lead Sponsor: Zydus Therapeutics Inc.